Modality
Gene Therapy
MOA
GLP-1/GIP
Target
IL-23
Pathway
Epigenetic
CSU
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
Jun 2023
→ Apr 2028
Phase 1Current
NCT07100579
1,054 pts·CSU
2023-06→2028-04·Recruiting
1,054 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-062mo agoEnrollment Complete· CSU
2028-04-132.0y awayInterim· CSU
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Recruit…
Catalysts
Enrollment Complete
2026-02-06 · 2mo ago
CSU
Interim
2028-04-13 · 2.0y away
CSU
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07100579 | Phase 1 | CSU | Recruiting | 1054 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |